|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01931 IVD MEDICAL
Nominal 
10.180 -0.220 (-2.115%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 1,269,595 | -6.197% | 3,162,415 | 3,088,387 | 2,748,809 | 2,730,670 |
| Cost of Sales | (990,001) | -3.769% | (2,411,242) | (2,416,686) | (2,140,668) | (2,164,402) |
| Gross Profit | 279,594 | -13.889% | 751,173 | 671,701 | 608,141 | 566,268 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 2,698 | -- | (9,468) | (20,631) | (11,455) | 13,918 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (6,032) | 53.917% | (18,829) | (22,659) | 2,795 | 8,335 | |
| Profit / (Loss) before Taxation | 71,844 | -60.195% | 401,777 | 339,329 | 283,789 | 267,940 | |
| Taxation | (33,518) | -36.669% | (135,743) | (102,203) | (88,259) | (106,190) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 793 | -- | (5,614) | 1,037 | 14,469 | 12,791 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 39,119 | -68.777% | 260,420 | 238,163 | 209,999 | 174,541 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 21,292 | 115.878% | 33,307 | 18,130 | 28,608 | 18,664 |
| Depreciation & Amortisation | 19,504 | -0.904% | 38,200 | 37,559 | 35,289 | 38,806 |
| Directors' Emoluments | -- | -- | 15,295 | 8,928 | 11,029 | 10,666 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 2.410 | -74.002% | 17.420 | 17.620 | 15.610 | 13.190 |
| DPS (cts) | 0.000 | -- | 0.000 | 8.325 | 7.251 | 6.602 |
| Dividend Payout Ratio (%) | -- | -- | -- | 47.247% | 46.451% | 50.052% |
| Cash flow per share ($) | -- | -- | 0.094 | 0.216 | 0.186 | 0.123 |
| NBV per share ($) | 2.138 | -- | 2.285 | 2.469 | 2.328 | 2.202 |
| Remarks: | Real time quote last updated: 11/09/2025 17:21 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 39,119 |
| %Change | -68.777% |
| EPS / (LPS) | RMB 0.024 |
| NBV Per Share (¥) | RMB 2.138 |